Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

chagas disease/protease

Odkaz sa uloží do schránky
ČlánkyKlinické štúdiePatenty
Strana 1 od 187 výsledky
BACKGROUND Chagas disease results from infection with the diploid protozoan parasite Trypanosoma cruzi. T. cruzi is highly genetically diverse, and multiclonal infections in individual hosts are common, but little studied. In this study, we explore T. cruzi infection multiclonality in the context of

[Cysteine-dependent protease in Trypanosoma cruzi useful for the diagnosis of Chagas disease].

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
An immunoenzymatic system on solid phase for the detection of IgG antibodies in serum from chronic Chagasic patients was standardized. A protease from Trypanosoma cruzi (GP57/51KDa) was used as an antigen. The sensitivity, specificity and predictive values of the procedure were calculated taking

Apolipoprotein A-I truncations in Chagas disease are caused by cruzipain, the major cysteine protease of Trypanosoma cruzi.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Trypanosoma cruzi is the etiologic agent of Chagas disease. Approximately 10 million people are infected worldwide. We have previously reported that in individuals infected with T. cruzi, apolipoprotein A-I (Apo A-I), the major structural component of host high-density lipoprotein, was truncated

[Trypanocidal effect of cysteine protease inhibitors in vitro and in vivo in experimental Chagas disease].

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Endemic in most American countries, Chagas' disease causes high morbidity and mortality. Recent experimental and clinical evidence shows the importance of chemotherapy in both the acute and chronic phases of this disease. However, treatment is yet limited by the toxicity associated to available

Deficiency in mannose-binding lectin-associated serine protease-2 does not increase susceptibility to Trypanosoma cruzi infection.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Trypanosoma cruzi is the causative agent of Chagas' disease, a chronic illness affecting 10 million people around the world. The complement system plays an important role in fighting microbial infections. The recognition molecules of the lectin pathway of complement activation, mannose-binding

Effects of a marine serine protease inhibitor on viability and morphology of Trypanosoma cruzi, the agent of Chagas disease.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
It has been reported that serine peptidase activities of Trypanosoma cruzi play crucial roles in parasite dissemination and host cell invasion and therefore their inhibition could affect the progress of Chagas disease. The present study investigates the interference of the Stichodactyla helianthus
Salivary anticoagulant activities are widely distributed among hematophagous arthropods. Most of them are inhibitors of the serine proteases of the coagulation cascade. Here we show that the saliva of the exclusively hematophagous insect Triatoma infestans, an important vector in the transmission of

Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Trypanosoma cruzi, a protozoan parasite, is the causative agent of Chagas disease, a major cause of cardiovascular disease in many Latin American countries. There is an urgent need to develop an improved therapy due to the toxicity of existing drugs and emerging drug resistance. Cruzain, the primary

Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Trypanosoma cruzi is the causative agent of Chagas' disease. The major protease, cruzain, is a target for the development of new chemotherapy. We report the first successful treatment of an animal model of Chagas' disease with inhibitors designed to inactivate cruzain. Treatment with fluoromethyl

A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
BACKGROUND Cysteine proteases of the papain superfamily are present in nearly all groups of eukaryotes and play vital roles in a wide range of biological processes and diseases, including antigen and hormone processing, bacterial infection, arthritis, osteoporosis, Alzheimer's disease and

Reversible cysteine protease inhibitors show promise for a Chagas disease cure.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The cysteine protease cruzipain is essential for the viability, infectivity, and virulence of Trypanosoma cruzi, the causative agent of Chagas disease. Thus, inhibitors of cruzipain are considered promising anti-T. cruzi chemotherapeutic agents. Reversible cruzipain inhibitors containing a nitrile

A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Chagas' disease, caused by the parasite Trypanosoma cruzi, remains the leading cause of cardiopathy in Latin America with about 12 million people infected. Classic clinical manifestations derive from infection of muscle cells leading to progressive cardiomyopathy, while some patients develop

Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Cruzain, a cysteine protease of Trypanosoma cruzi, is a validated target for the treatment of Chagas disease. Due to its high similarity in three-dimensional structure with human cathepsins and their sequence identity above 70% in the active site regions, identifying potent but selective cruzain

General solid-phase method to prepare novel cyclic ketone inhibitors of the cysteine protease cruzain.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
A series of constrained ketone-based inhibitors has been developed that show low nanomolar Ki values. These ketone inhibitors showed promising activity towards cruzain, the cysteine protease implicated in Chagas' disease. This series of constrained inhibitors, which can be accessed quickly and

Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.

Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
K02 (morpholine-urea-Phe-Hphe-vinylsulfone), a newly developed peptidomimetic, acts as a potent cysteine protease inhibitor, especially of cathepsins B and L (which are associated with cancer progression) and cruzain (a cysteine protease of Trypanosoma cruzi, which is responsible for Chagas'
Pripojte sa k našej
facebookovej stránke

Najkompletnejšia databáza liečivých bylín podporovaná vedou

  • Pracuje v 55 jazykoch
  • Bylinné lieky podporené vedou
  • Rozpoznávanie bylín podľa obrázka
  • Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
  • Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
  • Vyhľadajte liečivé byliny podľa ich účinkov
  • Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume

Google Play badgeApp Store badge